These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 28012496)

  • 1. An autopsy case of bronchiolitis obliterans as a previously unrecognized adverse event of afatinib treatment.
    Kanaji N; Chiba Y; Sato A; Ueno M; Tadokoro A; Kita N; Ishii T; Watanabe N; Kadowaki N; Bandoh S
    Respir Investig; 2017 Jan; 55(1):58-62. PubMed ID: 28012496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
    Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
    Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors.
    Heigener DF; Schumann C; Sebastian M; Sadjadian P; Stehle I; Märten A; Lüers A; Griesinger F; Scheffler M;
    Oncologist; 2015 Oct; 20(10):1167-74. PubMed ID: 26354527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer.
    Takeda M; Okamoto I; Nakagawa K
    Lung Cancer; 2015 Apr; 88(1):74-9. PubMed ID: 25704957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial.
    Yang JC; Shih JY; Su WC; Hsia TC; Tsai CM; Ou SH; Yu CJ; Chang GC; Ho CL; Sequist LV; Dudek AZ; Shahidi M; Cong XJ; Lorence RM; Yang PC; Miller VA
    Lancet Oncol; 2012 May; 13(5):539-48. PubMed ID: 22452895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Independent review of interstitial lung disease associated with death in TRIBUTE (paclitaxel and carboplatin with or without concurrent erlotinib) in advanced non-small cell lung cancer.
    Yoneda KY; Shelton DK; Beckett LA; Gandara DR
    J Thorac Oncol; 2007 Jun; 2(6):537-43. PubMed ID: 17545850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Afatinib-associated Stevens-Johnson syndrome in an EGFR-mutated lung cancer patient.
    Doesch J; Debus D; Meyer C; Papadopoulos T; Schultz ES; Ficker JH; Brueckl WM
    Lung Cancer; 2016 May; 95():35-8. PubMed ID: 27040849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Afatinib and lung cancer.
    Jain P; Khanal R; Sharma A; Yan F; Sharma N
    Expert Rev Anticancer Ther; 2014 Dec; 14(12):1391-406. PubMed ID: 25417728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful treatment with erlotinib after gefitinib-induced interstitial lung disease: a case report and literature review.
    Koma Y; Matsuoka H; Yoshimatsu H; Suzuki Y
    Int J Clin Pharmacol Ther; 2012 Oct; 50(10):760-4. PubMed ID: 22853866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: comparison with historical cohort using erlotinib.
    Lee VH; Leung DK; Choy TS; Lam KO; Lam PM; Leung TW; Kwong DL
    BMC Cancer; 2016 Feb; 16():147. PubMed ID: 26911310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial.
    Soria JC; Felip E; Cobo M; Lu S; Syrigos K; Lee KH; Göker E; Georgoulias V; Li W; Isla D; Guclu SZ; Morabito A; Min YJ; Ardizzoni A; Gadgeel SM; Wang B; Chand VK; Goss GD;
    Lancet Oncol; 2015 Aug; 16(8):897-907. PubMed ID: 26156651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bronchiolitis obliterans in a patient with localized scleroderma treated with D-penicillamine.
    Boehler A; Vogt P; Speich R; Weder W; Russi EW
    Eur Respir J; 1996 Jun; 9(6):1317-9. PubMed ID: 8804954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Anatomoclinical diversity of bronchiolitis obliterans after lung transplantation. Anatomical study of 16 cases among 64 transplantations].
    Loire R; Brune J; Cordier JF; Mornex JF; Philit F; Roux N; Tabib A
    Arch Anat Cytol Pathol; 1993; 41(5-6):232-9. PubMed ID: 8135585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A new perspective in the treatment of non-small-cell lung cancer (NSCLC). Role of afatinib: An oral and irreversible ErbB family blocker].
    Wislez M; Malka D; Bennouna J; Mortier L; Bensadoun RJ; Sicard J; Dielenseger P; Rey JB; Moro-Sibilot D; Scotté F
    Bull Cancer; 2014 Jun; 101(6):647-52. PubMed ID: 24977454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cutaneous side-effects of epidermal growth factor receptor-tyrosine kinase inhibitor (TKI) in the treatment of lung cancer: description and its management.
    Ong CK; Tan WC; Chan LC; Abdul Razak M
    Med J Malaysia; 2012 Apr; 67(2):222-3. PubMed ID: 22822651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4).
    Murakami H; Tamura T; Takahashi T; Nokihara H; Naito T; Nakamura Y; Nishio K; Seki Y; Sarashina A; Shahidi M; Yamamoto N
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):891-9. PubMed ID: 22071596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Hange-Shashin-to for preventing diarrhea during afatinib therapy].
    Yamaguchi O; Kawashima A; Shiono A; Maeno Y; Ishikawa R; Masumoto A; Utsugi H; Daito H; Okano T; Murayama Y; Kobayashi K
    Gan To Kagaku Ryoho; 2015 May; 42(5):581-3. PubMed ID: 25981651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a skin rash within the first week and the therapeutic effect in afatinib monotherapy for EGFR-mutant non-small cell lung cancer (NSCLC): Okayama Lung Cancer Study Group experience.
    Kudo K; Hotta K; Bessho A; Nogami N; Kozuki T; Kuyama S; Inoue K; Harita S; Okada T; Gemba K; Fujii M; Takigawa N; Oda N; Tanimoto M; Kiura K
    Cancer Chemother Pharmacol; 2016 May; 77(5):1005-9. PubMed ID: 27029623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The safety of afatinib for the treatment of non-small cell lung cancer.
    Barron F; de la Torre-Vallejo M; Luna-Palencia RL; Cardona AF; Arrieta O
    Expert Opin Drug Saf; 2016 Nov; 15(11):1563-1572. PubMed ID: 27633264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer.
    Yonesaka K; Kudo K; Nishida S; Takahama T; Iwasa T; Yoshida T; Tanaka K; Takeda M; Kaneda H; Okamoto I; Nishio K; Nakagawa K
    Oncotarget; 2015 Oct; 6(32):33602-11. PubMed ID: 26418897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.